Gilead Sciences Inc (GILD) Stock Rating

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with its portfolio centered on HIV and hepatitis B and C. Its acquisition of Pharmasset brought the hepatitis C drug Sovaldi, now part of newer standard-of-care combination regimens, and it is expanding in oncology, led by the CAR-T cell therapy Yescarta/Tecartus (from Kite) and the breast and bladder cancer therapy Trodelvy (from Immunomedics).

Rating as of 2026-07-07. Live price updates in real time.